Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer

Abstract

Background

Breast cancer is the most common malignancy diagnosed in women of childbearing age. A breast cancer diagnosis in this young patient population can be uniquely complex to navigate when considering the potential impact of fertility loss associated with specific gonadotoxic therapies. Another unique challenge for young breast cancer patients is pregnancy-associated breast cancer (PABC), which occurs in approximately 1 of every 3000 pregnancies. Pregnancy adds a layer of complexity to breast cancer treatment planning as many therapies can affect the developing fetus. These two clinical challenges require nuanced multidisciplinary approaches to facilitate optimal treatment outcomes. We sought to review and summarize the management strategy options for both fertility preservation and PABC.

Methods

A guideline and literature review was performed for fertility preservation, young patients with breast cancer, and pregnancy-associated breast cancer.

Results

Fertility preservation options, both established and experimental, are detailed. Suggested clinical practice guidelines for PABC are also presented, which delineate breast cancer treatment recommendations based on pregnancy trimester.

Conclusion

A multidisciplinary approach to patient care, including oncologists and early referral to reproductive specialists, can provide young breast cancer patients with options for fertility preservation. Under the guidance of a multidisciplinary treatment team, PABC can also be diagnosed and treated to permit the best possible outcomes for the mother and the developing fetus.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    American Cancer Society. Breast cancer facts & figures. American Cancer Society, Atlanta; 2017.

  2. 2.

    Rosenberg SM, Newman LA, Partridge AH. Breast cancer in young women: rare disease or public health problem? JAMA Oncol. 2015;1:877–8.

  3. 3.

    Pavlidis N, Pentheroudakis G. The pregnant mother with breast cancer: diagnostic and therapeutic management. Cancer Treat Rev. 2005;31:439–47.

  4. 4.

    Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–32.

  5. 5.

    Christinat A, Pagani O. Fertility after breast cancer. Maturitas. 2012;73:191–6.

  6. 6.

    Lambertini M, Goldrat O, Clatot F, Demeestere I, Awada A. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol. 2017;29:243–52.

  7. 7.

    Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32:1151–6.

  8. 8.

    Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1994–2001.

  9. 9.

    Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–17.

  10. 10.

    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy, and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–70.

  11. 11.

    Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7:279–87.

  12. 12.

    Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27:45–51.

  13. 13.

    Johansson ALV, Andersson TM, Hsieh CC, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer. 2018;142:1343–54.

  14. 14.

    Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during, and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 2016;160:347–60.

  15. 15.

    Network NCC. Breast Cancer Version (1.2018), 2018. Retrieved July 2018 at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  16. 16.

    Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015;1:1145–53.

  17. 17.

    Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360:902–11.

  18. 18.

    Antypas C, Sandilos P, Kouvaris J, et al. Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 1998;40:995–9.

  19. 19.

    Mazonakis M, Varveris H, Damilakis J, Theoharopoulos N, Gourtsoyiannis N. Radiation dose to conceptus resulting from tangential breast irradiation. Int J Radiat Oncol Biol Phys. 2003;55:386–91.

  20. 20.

    Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res. 2014;6:105–17.

  21. 21.

    Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151:589–96.

  22. 22.

    Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29:1110–6.

  23. 23.

    Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145:113–28.

  24. 24.

    Lambertini M, Campbell C, Bines J, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2018. https://doi.org/10.1093/jnci/djy094.

  25. 25.

    Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791–8.

  26. 26.

    Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:349–57.

  27. 27.

    Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–37.

  28. 28.

    Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.

  29. 29.

    Llarena NC, Estevez SL, Tucker SL, Jeruss JS. Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst. 2015. https://doi.org/10.1093/jnci/djv202

  30. 30.

    Lambertini M, Kroman N, Ameye L, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018;110:426–9.

  31. 31.

    IBCSG 48-14 POSITIVE Trial. Retrieved 15 May 2018 at http://www.ibcsg.org/Public/Health_Professionals/Open_Trials/ibcsg_48-14_positive/Pages/IBCSG48-14POSITIVE.aspx.

  32. 32.

    Pagani O, Ruggeri M, Manunta S, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24:201–7.

  33. 33.

    van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.

  34. 34.

    Freour T, Barriere P, Masson D. Anti-mullerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017;74:1–8.

  35. 35.

    Dezellus A, Barriere P, Campone M, et al. Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017;79:72–80.

  36. 36.

    Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017;87:58–64.

  37. 37.

    Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2500–10.

  38. 38.

    von Wolff M, Thaler CJ, Frambach T, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009;92:1360–5.

  39. 39.

    Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet. 2012;29:503–5.

  40. 40.

    Sonmezer M, Turkcuoglu I, Coskun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95:2125-e9.

  41. 41.

    Practice Committee of American Society for Reproductive Medicine (2013) Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 100:1214–23.

  42. 42.

    Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet. 2010;27:491–4.

  43. 43.

    Moravek MB, Confino R, Smith KN, et al. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109:349–55.

  44. 44.

    Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26:2630–5.

  45. 45.

    Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101:1364–71.

  46. 46.

    Ayhan A, Salman MC, Celik H, Dursun P, Ozyuncu O, Gultekin M. Association between fertility drugs and gynecologic cancers, breast cancer, and childhood cancers. Acta Obstet Gynecol Scand. 2004;83:1104–11.

  47. 47.

    Lambertini M, Goldrat O, Ferreira AR, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29:237–43.

  48. 48.

    Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2018;25:26–32.

  49. 49.

    Cobo A, Meseguer M, Remohi J, Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. Hum Reprod. 2010;25:2239–46.

  50. 50.

    Ho JR, Woo I, Louie K, et al. A comparison of live birth rates and perinatal outcomes between cryopreserved oocytes and cryopreserved embryos. J Assist Reprod Genet. 2017;34:1359–66.

  51. 51.

    Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011;2011(11):CD008018.

  52. 52.

    Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95:906–14.e1–4.

  53. 53.

    Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast. 2013;22:150–7.

  54. 54.

    Bai F, Lu Y, Wu K, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care Basel. 2017;12:48–52.

  55. 55.

    Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–19.

  56. 56.

    Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36:1981–90.

  57. 57.

    Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25–33.

  58. 58.

    Pacheco F, Oktay K. Current success and efficiency of autologous ovarian transplantation: a meta-analysis. Reprod Sci. 2017;24:1111–20.

  59. 59.

    Meirow D, Hardan I, Dor J, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. Hum Reprod. 2008;23:1007–13.

  60. 60.

    Telfer EE, McLaughlin M, Ding C, Thong KJ. A two-step serum-free culture system supports development of human oocytes from primordial follicles in the presence of activin. Hum Reprod. 2008;23:1151–8.

  61. 61.

    Xu M, Kreeger PK, Shea LD, Woodruff TK. Tissue-engineered follicles produce live, fertile offspring. Tissue Eng. 2006;12:2739–46.

  62. 62.

    Laronda MM, Duncan FE, Hornick JE, et al. Alginate encapsulation supports the growth and differentiation of human primordial follicles within ovarian cortical tissue. J Assist Reprod Genet. 2014;31:1013–28.

  63. 63.

    Rios PD, Kniazeva E, Lee HC, et al. Retrievable hydrogels for ovarian follicle transplantation and oocyte collection. Biotechnol Bioeng. 2018;115:2075–86.

  64. 64.

    Daly MB, Pilarski R, Berry MP, Buys SS, Friedman S, Garber JE, et al. Genetic/familial high-risk assessment: breast and ovarian, Version 1.2018, 2017. Retrieved 14 May 2018 at https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

  65. 65.

    Committee on Practice Bulletins-Gynecology CoGSoGO. Practice Bulletin No 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017;130:e110–26.

  66. 66.

    Robbins J, Jeffries D, Roubidoux M, Helvie M. Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation. AJR Am J Roentgenol. 2011;196:716–22.

  67. 67.

    Carmichael H, Matsen C, Freer P, et al. Breast cancer screening of pregnant and breastfeeding women with BRCA mutations. Breast Cancer Res Treat. 2017;162:225–30.

  68. 68.

    Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: Part 1. Evidence-based review and recommendations. AJR Am J Roentgenol. 2012;198:778–84.

  69. 69.

    Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46:3158–68.

  70. 70.

    Bulas D, Egloff A. Benefits and risks of MRI in pregnancy. Semin Perinatol. 2013;37:301–4.

  71. 71.

    Vashi R, Hooley R, Butler R, Geisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. AJR Am J Roentgenol. 2013;200:321–8.

  72. 72.

    Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012;379:570–9.

  73. 73.

    Peccatori FA, Codacci-Pisanelli G, Del Grande M, Scarfone G, Zugni F, Petralia G. Whole-body MRI for systemic staging of breast cancer in pregnant women. Breast. 2017;35:177–81.

  74. 74.

    Takalkar AM, Khandelwal A, Lokitz S, Lilien DL, Stabin MG. 18F-FDG PET in pregnancy and fetal radiation dose estimates. J Nucl Med. 2011;52:1035–40.

  75. 75.

    Zanotti-Fregonara P, Laforest R, Wallis JW. Fetal radiation dose from 18F-FDG in pregnant patients imaged with PET, PET/CT, and PET/MR. J Nucl Med. 2015;56:1218–22.

  76. 76.

    Committee on Obstetric Practice and the American Society of Anesthesiologists. Committee opinion no. 696: nonobstetric surgery during pregnancy. Obstet Gynecol. 2017;129:777–8.

  77. 77.

    Cheek TG, Baird E. Anesthesia for nonobstetric surgery: maternal and fetal considerations. Clin Obstet Gynecol. 2009;52:535–45.

  78. 78.

    Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002;194:54–64.

  79. 79.

    Caragacianu DL, Mayer EL, Chun YS, et al. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. J Surg Oncol. 2016;114:140–3.

  80. 80.

    Lohsiriwat V, Peccatori FA, Martella S, et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast. 2013;22:657–60.

  81. 81.

    Han SN, Amant F, Cardonick EH, et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. Breast Cancer Res Treat. 2018;168:551–7.

  82. 82.

    Shlensky V, Hallmeyer S, Juarez L, Parilla BV. Management of breast cancer during pregnancy: are we compliant with current guidelines? AJP Rep. 2017;7:e39–e43.

  83. 83.

    Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16:1143–7.

  84. 84.

    Keleher A, Wendt R III, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99 m sulfur colloid. Breast J. 2004;10:492–5.

  85. 85.

    Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47:1202–8.

  86. 86.

    Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imag. 2010;37:78–83.

  87. 87.

    Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol. 2014;21:2506–11.

  88. 88.

    Valentin J. Biological effects after prenatal irradiation (embryo and fetus): ICRP Publication 90 approved by the commission in October 2002. Ann ICRP. 2003;33:1–206.

  89. 89.

    Deckers S, Amant F. Breast cancer in pregnancy: a literature review. Facts Views Vis Obgyn. 2009;1:130–41.

  90. 90.

    Leal SC, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: a review. Expert Rev Anticancer Ther. 2013;13:159–64.

  91. 91.

    Azim HA, Jr., Del Mastro L, Scarfone G, Peccatori FA. Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring, and more. Breast. 2011;20:1–6.

  92. 92.

    Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents, and immunotherapy during pregnancy: Part I. Solid tumors. Cancer Treat Rev. 2010;36:101–9.

  93. 93.

    de Haan J, Verheecke M, Van Calsteren K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018;19:337–46.

  94. 94.

    Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13:256–64.

  95. 95.

    Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015;212:658-e651–8.

  96. 96.

    Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373:1824–34.

  97. 97.

    Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010;16:76–82.

  98. 98.

    Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13:887–96.

  99. 99.

    Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107:1219–26.

  100. 100.

    Peccatori FA, Azim HA Jr, Scarfone G, et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009;115:591–4.

  101. 101.

    Zagouri F, Sergentanis TN, Chrysikos D, et al. Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer. 2013;13:16–23.

  102. 102.

    Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol. 2012;23:3016–23.

  103. 103.

    Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in pregnancy and lactation, 11 edn. Wolters Kluwer, Alphen aan den Rijn; 2017.

  104. 104.

    Lambertini M, Peccatori FA, Azim HA Jr. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41:301–9.

  105. 105.

    Maly JJ, Macrae ER. Pertuzumab in combination with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression-free survival. Breast Cancer Auckl. 2014;8:81–8.

  106. 106.

    Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16:1547–51.

  107. 107.

    Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28:1811–6.

  108. 108.

    Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334–41.

  109. 109.

    Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314:2632–40.

  110. 110.

    Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533–8.

Download references

Acknowledgment

The authors thank Zachary Pascoe for helpful discussions regarding manuscript preparation. The authors acknowledge financial support from the NIH R01CA214384 (to J. S. Jeruss), A Sister’s Hope Foundation, (J. S. Jeruss), and NIH T32CA009672 (J. S. Jeruss and P. Kandagatla).

Author information

Correspondence to Jacqueline S. Jeruss MD, Ph.D..

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shah, N.M., Scott, D.M., Kandagatla, P. et al. Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer. Ann Surg Oncol 26, 1214–1224 (2019). https://doi.org/10.1245/s10434-019-07156-7

Download citation